Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 79b0ccaa31e45b1cabf45b9a1cdb8ef56178fd73
First added on: Feb 12, 2025